ORAVIG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORAVIG (ORAVIG).
Miconazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative pathways; negligible systemic absorption after buccal administration. |
| Excretion | Primarily fecal (approximately 52%) with 39% of the dose recovered in urine; less than 0.5% of the dose is excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 24 hours, supporting once-daily buccal administration for sustained local oropharyngeal concentrations. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 4.0 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Systemic bioavailability is approximately 25% after buccal administration due to first-pass metabolism and local retention; absorption is primarily buccal. |
| Onset of Action | Within 2–4 hours after buccal application, measurable salivary concentrations; clinical antifungal effect observed within 24 hours. |
| Duration of Action | Therapeutic local concentrations persist for at least 24 hours after a single buccal tablet application, allowing once-daily dosing. |
ORAVIG (miconazole) 50 mg buccal tablet applied once daily to the upper gum region (canine fossa) for 14 consecutive days. The tablet is placed with the rounded side against the gum and held in place for 30 seconds to ensure adhesion.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment; the systemic absorption is minimal (1-2%) and miconazole is primarily hepatically metabolized with less than 1% excreted renally as unchanged drug. |
| Liver impairment | No specific dosing recommendations for hepatic impairment; caution is advised in severe hepatic dysfunction due to potential for increased systemic exposure, though clinical significance is unknown given minimal absorption. |
| Pediatric use | Safety and efficacy in pediatric patients below 16 years of age have not been established; no recommended dosing. |
| Geriatric use | No specific dose adjustment required in elderly patients; clinical studies included patients aged 65 and older with no overall differences in safety or effectiveness, but caution is advised due to potential age-related mucosal changes or concomitant medications. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORAVIG (ORAVIG).
| Breastfeeding | It is not known whether miconazole is excreted in human milk after buccal administration. Miconazole is excreted in milk in animals. Caution should be exercised when ORAVIG is administered to a nursing woman. M/P ratio: not available. Consider developmental and health benefits of breastfeeding along with the mother's clinical need for ORAVIG and potential adverse effects on the breastfed infant. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, miconazole (the active ingredient) administered orally at doses up to 200 mg/kg/day (approximately 5 times the human dose based on body surface area) showed embryotoxicity and fetotoxicity. Risk cannot be ruled out. Use only if potential benefit justifies potential risk to the fetus. First trimester: avoid unless essential. Second and third trimesters: limited data, caution advised. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to miconazole or any component of the formulation.","Known hypersensitivity to other azole antifungals."]
| Precautions | ["Hypersensitivity reactions including urticaria, pruritus, and angioedema.","Local irritation, edema, or blistering at application site.","Risk of aspiration if tablet not properly placed on gum.","Avoid use in patients with severe hepatic impairment.","Not for systemic fungal infections."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of hepatotoxicity (elevated liver enzymes, jaundice) and allergic reactions. In pregnant women, fetal monitoring may include ultrasound to assess fetal growth if prolonged use. No specific maternal-fetal monitoring required for short-term topical buccal use. However, due to systemic absorption, periodic liver function tests may be considered in pregnant patients with hepatic impairment. |
| Fertility Effects | No specific studies on fertility in humans. In animal studies, miconazole did not impair fertility in rats at oral doses up to 200 mg/kg/day. However, high doses may cause hormonal disturbances. No known effect on human fertility with buccal administration. |